Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI content correctly references and aligns with the supplied label excerpts for suicidality risk and pediatric use/approval status (sections 5, 12, and 8.1). However, the target user claim to be evaluated is absent, limiting precision of claim-by-claim verification.
Category Scores
Accurate Statements
Antidepressants increased risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies, and the label requires balancing risk with clinical need and close monitoring.
Section 5 WARNINGS (boxed warning / clinical worsening & suicide risk) and Section 12 (clinical worsening and suicide risk).
NORPRAMIN is not approved for pediatric patients / not recommended for use in children.
Section 5 WARNINGS: 'NORPRAMIN is not approved for use in pediatric patients.' and Section 8.1 (Pediatric Use): 'NORPRAMIN ... is not recommended for use in children.'
The pooled analyses include children, adolescents, and young adults (ages 18 to 24), and it is unknown whether risk extends to longer-term use.
Section 12 CLINICAL PHARMACOLOGY excerpt.
Families and caregivers should be alerted and daily observation/close observation is recommended.
Section 5 WARNINGS and Section 12 CLINICAL PHARMACOLOGY excerpts.
Unsupported Statements
The evaluation target assessment is 'absent_from_the_label' and 'assessment_details: given_user_claim null; claim_evaluated false.'
No specific user claim text was provided to verify; therefore, these meta-claims about claim evaluation cannot be confirmed against the label excerpts.
Contradictions
Important Omissions
No specific user claim text was provided, so the report cannot verify whether any particular claim about suicidality/pediatric use (e.g., age range, wording about approval vs recommendation, or monitoring requirements) was accurately mapped to the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The content that addresses pediatric suicidality risk and pediatric approval status aligns with the supplied label excerpts and does not introduce contradictory dosing or treatment claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
No user claim text was supplied for precise claim-by-claim label mapping.
Suggested Improvement
Provide the exact user claim you want assessed (verbatim) so each element (risk, age group, approval/recommendation status, and monitoring language) can be directly matched to the corresponding label sentences.